Protein biomarkers of alcohol abuse

Expert Review of Proteomics

Volumn 9, Issue 4, 2012, Pages 425-436

  Torrente, Mariana P ^a   Freeman, Willard M ^a   Vrana, Kent E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

alcohol abuse and dependence; biomarkers; DIGE; ethanol; mass spectrometry; proteomics

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHOL; ACETALDEHYDE; ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; CARBOHYDRATE DEFICIENT TRANSFERRIN; CYTOKINE; ETHYL GLUCURONIDE; GAMMA GLUTAMYLTRANSFERASE; PHOSPHATIDYLETHANOLAMINE; PROTEIN; SIALIC ACID;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; HUMAN; MASS SPECTROMETRY; MEAN CORPUSCULAR VOLUME; PROTEIN ANALYSIS; PROTEOMICS; REVIEW;

AFFINITY LABELS; ALCOHOL DRINKING; ALCOHOL-INDUCED DISORDERS; ALCOHOLISM; BIOLOGICAL MARKERS; CLUSTERIN; CYTOKINES; GLYCEROPHOSPHOLIPIDS; HUMANS; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TRANSFERRIN;

EID: 84866315167     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.38     Document Type: Review

References (99)

1. Parry CD, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: Epidemiology and policy implications. Addiction 106(10), 1718-1724 (2011).
2. Greenfield TK, Ye Y, Kerr W, Bond J, Rehm J, Giesbrecht N. Externalities from alcohol consumption in the 2005 US National Alcohol Survey: Implications for policy. Int. J. Environ. Res. Public Health 6(12), 3205-3224 (2009).
3. Harwood HJ, Fountain D, Livermore G. Economic costs of alcohol abuse and alcoholism. Recent Dev. Alcohol. 14, 307-330 (1998).
4. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373(9682), 2223-2233 (2009).
5. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol. Clin. Exp. Res. 31(7), 1208-1217 (2007). (Pubitemid 46934387)
6. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 252(14), 1905-1907 (1984). (Pubitemid 14002155)
7. Anton RF. Editorial commentary: Alcohol biomarker papers. Alcohol. Clin. Exp. Res. 34(6), 939-940 (2010).
8. Fuller RK, Lee KK, Gordis E. Validity of self-report in alcoholism research: Results of a Veterans Administration Cooperative Study. Alcohol. Clin. Exp. Res. 12(2), 201-205 (1988).
9. Tavakoli HR, Hull M, Michael Okasinski L. Review of current clinical biomarkers for the detection of alcohol dependence. Innov. Clin. Neurosci. 8(3), 26-33 (2011).
10. Kalapatapu RK, Chambers R. Novel objective biomarkers of alcohol use: potential diagnostic and treatment management tools in dual diagnosis care. J. Dual Diagn. 5(1), 57-82 (2009).
11. Freeman WM, Vrana KE. Future prospects for biomarkers of alcohol consumption and alcohol-induced disorders. Alcohol. Clin. Exp. Res. 34(6), 946-954 (2010).
12. Bearer CF, Bailey SM, Hoek JB. Advancing alcohol biomarkers research. Alcohol. Clin. Exp. Res. 34(6), 941-945 (2010).
13. Biomarkers Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
14. Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2(46), 46ps42 (2010).
15. Goodsaid F, Bandow JE, Mischak H. Grand rounds in proteomics at the FDA white oak, silver spring, MD, USA, April 3, 2007. Proteomics. Clin. Appl. 1(12), 1526-1531 (2007).
16. Litten RZ, Fertig J. Self-report and biochemical measures of alcohol consumption. Addiction 98(Suppl. 2), iii-iiv (2003).
17. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: Recent advances and future research opportunities. Alcohol. Clin. Exp. Res. 34(6), 955-967 (2010).
18. Joya X, Friguls B, Ortigosa S et al. Determination of maternal-fetal biomarkers of prenatal exposure to ethanol: A review. J. Pharm. Biomed. Anal. 69, 209-222 (2012).
19. Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ. Biochemical markers of alcoholism. Clin. Chem. Lab. Med. 45(8), 953-961 (2007). (Pubitemid 47424855)
20. Niemelä O. Biomarkers in alcoholism. Clin. Chim. Acta 377(1-2), 39-49 (2007).
21. Kissack JC, Bishop J, Roper AL. Ethylglucuronide as a biomarker for ethanol detection. Pharmacotherapy 28(6), 769-781 (2008). (Pubitemid 351975380)
22. Helander A, Böttcher M, Fehr C, Dahmen N, Beck O. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol. 44(1), 55-61 (2009).
23. Thierauf A, Wohlfarth A, Auwärter V, Perdekamp MG, Wurst FM, Weinmann W. Urine tested positive for ethyl glucuronide and ethyl sulfate after the consumption of yeast and sugar. Forensic Sci. Int. 202(1-3), e45-e47 (2010).
24. Høiseth G, Morini L, Polettini A, Christophersen A, Mørland J. Ethyl glucuronide in hair compared with traditional alcohol biomarkers - a pilot study of heavy drinkers referred to an alcohol detoxification unit. Alcohol. Clin. Exp. Res. 33(5), 812-816 (2009).
25. Kharbouche H, Faouzi M, Sanchez N et al. Diagnostic performance of ethyl glucuronide in hair for the investigation of alcohol drinking behavior: A comparison with traditional biomarkers. Int. J. Legal Med. 126(2), 243-250 (2012).
26. Morini L, Colucci M, Ruberto MG, Groppi A. Determination of ethyl glucuronide in nails by liquid chromatography tandem mass spectrometry as a potential new biomarker for chronic alcohol abuse and binge drinking behavior. Anal. Bioanal. Chem. 402(5), 1865-1870 (2012).
27. Junghanns K, Graf I, Pflüger J et al. Urinary ethyl glucuronide (EtG) and ethyl sulphate (EtS) assessment: Valuable tools to improve verification of abstention in alcohol-dependent patients during in-patient treatment and at follow-ups. Addiction 104(6), 921-926 (2009).
28. Helander A, Beck O. Ethyl sulfate: A metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J. Anal. Toxicol. 29(5), 270-274 (2005). (Pubitemid 41191694)
29. Javors MA, Johnson BA. Current status of carbohydrate deficient transferrin, total serum sialic acid, sialic acid index of apolipoprotein J and serum beta hexosaminidase as markers for alcohol consumption. Addiction 98(Suppl. 2), 45-50 (2003).
30. Sillanaukee P, Pönniö M, Seppä K. Sialic acid: New potential marker of alcohol abuse. Alcohol. Clin. Exp. Res. 23(6), 1039-1043 (1999). (Pubitemid 29283499)
31. Chrostek L, Cylwik B, Korcz W et al. Serum free sialic acid as a marker of alcohol abuse. Alcohol. Clin. Exp. Res. 31(6), 996-1001 (2007). (Pubitemid 46776178)
32. Chrostek L, Cylwik B, Krawiec A, Korcz W, Szmitkowski M. Relationship between serum sialic acid and sialylated glycoproteins in alcoholics. Alcohol Alcohol. 42(6), 588-592 (2007). (Pubitemid 350028202)
33. Kurtul N, Cil MY, Bakan E. The effects of alcohol and smoking on serum, saliva, and urine sialic acid levels. Saudi Med. J. 25(12), 1839-1844 (2004). (Pubitemid 40253652)
34. Joshi M, Patil R. Estimation and comparative study of serum total sialic acid levels as tumor markers in oral cancer and precancer. J. Cancer Res. Ther. 6(3), 263-266 (2010).
35. Ur Rahman I, Idrees M, Salman M et al. A comparison of the effect of glitazones on serum sialic acid in patients with Type 2 diabetes. Diab. Vasc. Dis. Res. 9(3), 238-240 (2012).
36. Alturfan AA, Uslu E, Alturfan EE, Hatemi G, Fresko I, Kokoglu E. Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. Tohoku J. Exp. Med. 213(3), 241-248 (2007). (Pubitemid 350238023)
37. Inayat Ur R, Malik SA, Bashir M, Khan R, Iqbal M. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment. Phytomedicine 16(5), 401-405 (2009).
38. Sillanaukee P, Pönniö M, Jääskeläinen IP. Occurrence of sialic acids in healthy humans and different disorders. Eur. J. Clin. Invest. 29(5), 413-425 (1999). (Pubitemid 29209762)
39. Beck O, Helander A. 5-hydroxytryptophol as a marker for recent alcohol intake. Addiction 98(Suppl. 2), 63-72 (2003). (Pubitemid 38030763)
40. Helander A, Eriksson CJ; WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence Investigators. Laboratory tests for acute alcohol consumption: Results of the WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence. Alcohol. Clin. Exp. Res. 26(7), 1070-1077 (2002).
41. Høiseth G, Bernard JP, Stephanson N et al. Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5 HIAA in a controlled drinking experiment. Alcohol Alcohol. 43(2), 187-191 (2008). (Pubitemid 351486387)
42. Borucki K, Schreiner R, Dierkes J et al. Detection of recent ethanol intake with new markers: Comparison of fatty acid ethyl esters in serum and of ethyl glucuronide and the ratio of 5-hydroxytryptophol to 5-hydroxyindole acetic acid in urine. Alcohol. Clin. Exp. Res. 29(5), 781-787 (2005). (Pubitemid 40686548)
43. Isaksson A, Walther L, Hansson T, Andersson A, Alling C. Phosphatidylethanol in blood (B-PEth): A marker for alcohol use and abuse. Drug Test. Anal. 3(4), 195-200 (2011).
44. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol. 41(4), 431-437 (2006).
45. Hartmann S, Aradottir S, Graf M et al. Phosphatidylethanol as a sensitive and specific biomarker: Comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydratedeficient transferrin. Addict. Biol. 12(1), 81-84 (2007). (Pubitemid 46405993)
46. Wurst FM, Alexson S, Wolfersdorf M et al. Concentration of fatty acid ethyl esters in hair of alcoholics: Comparison to other biological state markers and self reportedethanol intake. Alcohol Alcohol. 39(1), 33-38 (2004). (Pubitemid 38111670)
47. Wurst FM, Thon N, Aradottir S et al. Phosphatidylethanol: Normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports. Addict. Biol. 15(1), 88-95 (2010).
48. Waszkiewicz N, Szajda SD, Kepka A, Szulc A, Zwierz K. Glycoconjugates in the detection of alcohol abuse. Biochem. Soc. Trans. 39(1), 365-369 (2011).
49. Sillanaukee P, Strid N, Allen JP, Litten RZ. Possible reasons why heavy drinking increases carbohydrate-deficient transferrin. Alcohol. Clin. Exp. Res. 25(1), 34-40 (2001). (Pubitemid 32147691)
50. Daves M, Cemin R, Floreani M, Pusceddu I, Cosio G, Lippi G. Comparative evaluation of capillary zone electrophoresis and HPLC in the determination of carbohydrate-deficient transferrin. Clin. Chem. Lab. Med. 49(10), 1677-1680 (2011).
51. Oberrauch W, Bergman AC, Helander A. HPLC and mass spectrometric characterization of a candidate reference material for the alcohol biomarker carbohydrate-deficient transferrin (CDT). Clin. Chim. Acta 395(1-2), 142-145 (2008).
52. Schellenberg F, Mennetrey L, Girre C, Nalpas B, Pagès JC. Automated measurement of carbohydrate-deficient transferrin using the Bio-Rad %CDT by the HPLC test on a variant HPLC system: Evaluation and comparison with other routine procedures. Alcohol Alcohol. 43(5), 569-576 (2008).
53. Reif A, Fallgatter AJ, Schmidtke A. Carbohydrate-deficient transferrin parallels disease severity in anorexia nervosa. Psychiatry Res. 137(1-2), 143-146 (2005). (Pubitemid 41550138)
54. Kenan N, Larsson A, Axelsson O, Helander A. Changes in transferrin glycosylation during pregnancy may lead to false-positive carbohydrate-deficient transferrin (CDT) results in testing for riskful alcohol consumption. Clin. Chim. Acta 412(1-2), 129-133 (2011).
55. Fleming MF, Anton RF, Spies CD. A review of genetic, biological, pharmacological, and clinical factors that affect carbohydrate-deficient transferrin levels. Alcohol. Clin. Exp. Res. 28(9), 1347-1355 (2004). (Pubitemid 39238293)
56. Ridinger M, Köhl P, Gäbele E et al. Analysis of carbohydrate deficient transferrin serum levels during abstinence. Exp. Mol. Pathol. 92(1), 50-53 (2012).
57. Neumann T, Spies C. Use of biomarkers for alcohol use disorders in clinical practice. Addiction 98(Suppl. 2), 81-91 (2003). (Pubitemid 38030765)
58. Targher G. Elevated serum gamma glutamyltransferase activity is associated with increased risk of mortality, incident Type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clin. Chem. Lab. Med. 48(2), 147-157 (2010).
59. Conigrave KM, Davies P, Haber P, Whitfield JB. Traditional markers of excessive alcohol use. Addiction 98(Suppl. 2), 31-43 (2003). (Pubitemid 38030760)
60. Kärkkäinen P, Jokelainen K, Roine R, Suokas A, Salaspuro M. The effects of moderate drinking and abstinence on serum and urinary beta-hexosaminidase levels. Drug Alcohol Depend. 25(1), 35-38 (1990). (Pubitemid 20086951)
61. Kärkkäinen P. Serum and urinary beta-hexosaminidase as markers of heavy drinking. Alcohol Alcohol. 25(4), 365-369 (1990). (Pubitemid 20285201)
62. Peterson K. Biomarkers for alcohol use and abuse - a summary. Alcohol Res. Health 28(1), 30-37 (2004). (Pubitemid 41595218)
63. De Benedetto GE, Fanigliulo M. A new CE-ESI-MS method for the detection of stable hemoglobin acetaldehyde adducts, potential biomarkers of alcohol abuse. Electrophoresis 30(10), 1798-1807 (2009).
64. Nicholls R, de Jersey J, Worrall S, Wilce P. Modification of proteins and other biological molecules by acetaldehyde: Adduct structure and functional significance. Int. J. Biochem. 24(12), 1899-1906 (1992).
65. Hietala J, Koivisto H, Latvala J, Anttila P, Niemelä O. IgAs against acetaldehydemodified red cell protein as a marker of ethanol consumption in male alcoholic subjects, moderate drinkers, and abstainers. Alcohol. Clin. Exp. Res. 30(10), 1693-1698 (2006). (Pubitemid 44465608)
66. Ghosh P, Hale EA, Lakshman MR. Plasma sialic-acid index of apolipoprotein J (SIJ): A new alcohol intake marker. Alcohol 5(3), 173-179 (2001). (Pubitemid 34143114)
67. Achur RN, Freeman WM, Vrana KE. Circulating cytokines as biomarkers of alcohol abuse and alcoholism. J. Neuroimmune Pharmacol. 5(1), 83-91 (2010).
68. Gonzalez-Quintela A, Campos J, Loidi L, Quinteiro C, Perez LF, Gude F. Serum TNF-alpha levels in relation to alcohol consumption and common TNF gene polymorphisms. Alcohol 42(6), 513-518 (2008).
69. Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Production of inflammatory cytokines by peripheral blood monocytes in chronic alcoholism: Relationship with ethanol intake and liver disease. Cytometry B. Clin. Cytom. 72(5), 408-415 (2007). (Pubitemid 350194358)
70. Chen J, Conigrave KM, Macaskill P, Whitfield JB, Irwig L; World Health Organization and the International Society for Biomedical Research on Alcoholism Collaborative Group. Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol Alcohol. 38(6), 574-582 (2003).
71. Sillanaukee P, Olsson U. Improved diagnostic classification of alcohol abusers by combining carbohydrate-deficient transferrin and gamma- glutamyltransferase. Clin. Chem. 47(4), 681-685 (2001). (Pubitemid 32275811)
72. Anton RF, Lieber C, Tabakoff B; CDTect Study Group. Carbohydrate- deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study. Alcohol. Clin. Exp. Res. 26(8), 1215-1222 (2002). (Pubitemid 34913207)
73. Rinck D, Frieling H, Freitag A et al. Combinations of carbohydrate-deficient transferrin, mean corpuscular erythrocyte volume, gamma-glutamyltransferase, homocysteine and folate increase the significance of biological markers in alcohol dependent patients. Drug Alcohol Depend. 89(1), 60-65 (2007). (Pubitemid 46602876)
74. Donato P, Cacciola F, Mondello L, Dugo P. Comprehensive chromatographic separations in proteomics. J. Chromatogr. A 1218(49), 8777-8790 (2011).
75. Kasinathan C, Vrana K, Beretta L et al. The future of proteomics in the study of alcoholism. Alcohol. Clin. Exp. Res. 28(2), 228-232 (2004). (Pubitemid 38233600)
76. Marshall T, Vesterberg O, Williams K. Effects of alcohol abuse on human serum proteins revealed by two-dimensional electrophoresis. Electrophoresis 5, 122-128 (1984). (Pubitemid 14107028)
77. Robinson MK, Myrick JE, Henderson LO et al. Two-dimensional protein electrophoresis and multiple hypothesis testing to detect potential serum protein biomarkers in children with fetal alcohol syndrome. Electrophoresis 16(7), 1176-1183 (1995).
78. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 70, 437-473 (2001). (Pubitemid 32662217)
79. Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J. Proteome Res. 10(1), 5-16 (2011).
80. Hiller-Sturmhöfel S, Sobin J, Mayfield RD. Proteomic approaches for studying alcoholism and alcohol-induced organ damage. Alcohol. Res. Health 31(1), 36-48 (2008).
81. Nomura F, Tomonaga T, Sogawa K, Wu D, Ohashi T. Application of proteomic technologies to discover and identify biomarkers for excessive alcohol consumption: A review. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855(1), 35-41 (2007). (Pubitemid 47082485)
82. Beranova-Giorgianni S. Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: Strengths and limitations. Trends. Analyt. Chem. 22(5), 273-281 (2003). (Pubitemid 36555941)
83. Guiochon G, Beaver LA. Separation science is the key to successful biopharmaceuticals. J. Chromatogr. A 1218(49), 8836-8858 (2011).
84. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001). (Pubitemid 32220565)
85. Plazas-Mayorca MD, Vrana KE. Proteomic investigation of epigenetics in neuropsychiatric disorders: A missing link between genetics and behavior? J. Proteome Res. 10(1), 58-65 (2011).
86. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat. Rev. Mol. Cell Biol. 5(9), 699-711 (2004). (Pubitemid 39208180)
87. Giebel R, Worden C, Rust SM, Kleinheinz GT, Robbins M, Sandrin TR. Microbial fingerprinting using matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) applications and challenges. Adv. Appl. Microbiol. 71, 149-184 (2010).
88. Nomura F, Tomonaga T, Sogawa K et al. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 4(4), 1187-1194 (2004). (Pubitemid 38445975)
89. Freeman WM, Gooch RS, Lull ME et al. Apo-AII is an elevated biomarker of chronic non-human primate ethanol self-administration. Alcohol Alcohol. 41(3), 300-305 (2006).
90. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 4(1), 51-65 (2007). (Pubitemid 46239472)
91. Kuklenyik Z, Boyer AE, Lins R et al. Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for endopeptidase activity-based quantification of anthrax lethal factor in serum. Anal. Chem. 83(5), 1760-1765 (2011).
92. Stoevesandt O, Taussig MJ, He M. Protein microarrays: high-throughput tools for proteomics. Expert Rev. Proteomics 6(2), 145-157 (2009).
93. Kingsmore SF. Multiplexed protein measurement: Technologies and applications of protein and antibody arrays. Nat. Rev. Drug Discov. 5(4), 310-320 (2006).
94. Sogawa K, Itoga S, Tomonaga T, Nomura F. Diagnostic values of surface-enhanced laser desorption/ionization technology for screening of habitual drinkers. Alcohol. Clin. Exp. Res. 31(Suppl. 1), S22-S26 (2007).
95. Sogawa K, Satoh M, Kodera Y, Tomonaga T, Iyo M, Nomura F. A search for novel markers of alcohol abuse using magnetic beads and MALDI-TOF/TOF mass spectrometry. Proteomics. Clin. Appl. 3(7), 821-828 (2009).
96. Sogawa K, Kodera Y, Satoh M et al. Increased serum levels of pigment epithelium-derived factor by excessive alcohol consumption-detection and identification by a three-step serum proteome analysis. Alcohol. Clin. Exp. Res. 35(2), 211-217 (2011).
97. Lai X, Liangpunsakul S, Crabb DW, Ringham HN, Witzmann FA. A proteomic workflow for discovery of serum carrier protein-bound biomarker candidates of alcohol abuse using LC-MS/MS. Electrophoresis 30(12), 2207-2214 (2009).
98. Freeman WM, Salzberg AC, Gonzales SW, Grant KA, Vrana KE. Classification of alcohol abuse by plasma protein biomarkers. Biol. Psychiatry 68(3), 219-222 (2010).
99. Freeman WM, Vanguilder HD, Guidone E, Krystal JH, Grant KA, Vrana KE. Plasma proteomic alterations in nonhuman primates and humans after chronic alcohol self-administration. Int. J. europsychopharmacol. 14(7), 899-911 (2011).